The study of Dipeptidyl peptidase-IV inhibitor's efficacy and safety when it is applied on type 2 diabetes whose blood sugar was poorly controlled with original oral antidiabetic drug
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2016
Price : $35 *
At a glance
- Drugs Saxagliptin (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Status changed from recruiting to completed, as reported at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 27 Nov 2013 New trial record